# ImmuneXcite

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunexcite

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.immunexcite.com
- Total disclosed funding: $8.6M
- Latest round: Series A (Mar 30, 2016)
- Investors on record: 3

## About

ImmuneXcite, Inc. is a biopharmaceutical firm focused on developing innovative therapies that enhance the immune response to fight serious diseases, particularly cancer and autoimmune disorders.Founded in 2007 in Lexington, US, ImmuneXcite, Inc. specializes in immunotherapy solutions. The company has undergone strategic shifts in its operational focus and successfully raised USD 8.6 mn in Series A funding in March 2016, attracting investment from Cormorant Asset Management, Mass General Brigham Ventures, and Sanofi Ventures. The total amount raised by the company to date is USD 8.6 mn.ImmuneXcite specializes in innovative biopharmaceutical products designed to enhance immune responses against various diseases. The core offerings include advanced immunotherapies aimed at treating conditions such as cancer and autoimmune disorders. These therapies work by utilizing mechanisms that stimulate the body’s immune system to recognize and attack diseased cells more effectively. Targeted primarily at healthcare providers, the end users of these products are patients undergoing treatment for serious medical conditions. The company distributes its products primarily in North America and Europe, focusing on partnerships with hospitals, cancer treatment centers, and specialty clinics to ensure accessibility for the patients in need.ImmuneXcite generates revenue through a combination of direct-to-consumer sales and strategic partnerships with healthcare institutions. The business model includes subscription-based access to certain therapeutic platforms along with one-time purchases of proprietary treatment regimens. Transactions typically occur through agreements with hospitals and oncology clinics, where healthcare providers purchase treatments for patient administration. Specific pricing structures for these therapies are established based on the complexity of the treatments and the associated healthcare costs. The flagship immunotherapy products, which are central to the company's offerings, are positioned to provide significant therapeutic benefits, thereby supporting the pricing strategy that reflects their advanced technological development.ImmuneXcite's future growth strategy includes the development of new immunotherapy products aimed at enhancing treatment options for patients with cancer and autoimmune disorders. The company is also planning to expand its presence in European markets by 2025, particularly focusing on partnerships with local healthcare providers to increase accessibility. The recent financing of USD 8.6 mn will be pivotal in supporting these initiatives, enabling the company to advance its product pipeline and execute its market expansion plans.

## Funding rounds

- Series A, Mar 30, 2016, $8.6M — Sanofi Ventures, Mass General Brigham Ventures, Cormorant Asset Management

## Investors

- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A